Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.
[BACKGROUND] The prognostic significance of high mobility group box 1 () expression in the non-small cell lung cancer (NSCLC) population remains controversial.
- 95% CI 0.91–1.29
- HR 1.51
- 연구 설계 meta-analysis
APA
Zheng T, Li X, et al. (2026). Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.. BMC cancer, 26(1), 184. https://doi.org/10.1186/s12885-025-15508-8
MLA
Zheng T, et al.. "Association of HMGB1 expression with prognosis of non-small cell lung cancer: a systematic review and meta-analysis.." BMC cancer, vol. 26, no. 1, 2026, pp. 184.
PMID
41486138
Abstract
[BACKGROUND] The prognostic significance of high mobility group box 1 () expression in the non-small cell lung cancer (NSCLC) population remains controversial. This study endeavors to systematically evaluate the relation of expression levels to NSCLC prognosis via a comprehensive meta-analysis.
[METHODS] Embase, the Cochrane Library, Web of Science, as well as PubMed were retrieved for eligible studies until September 18, 2025. Two reviewers independently extracted relevant data and appraised the study quality. The study quality was examined via the Newcastle-Ottawa Scale (NOS). Hazard Ratio (HR) with corresponding confidence intervals (CIs) for survival outcomes were calculated and summarized respectively. Subgroup analysis, regression analysis, sensitivity analysis and publication bias were conducted to investigate the findings further.
[RESULTS] 11 studies on 4,527 NSCLC patients were encompassed. All eligible studies had high methodological quality. The pooled HR of OS was 1.08 (95% CI: 0.91–1.29, = 0.356), suggesting no significant association of expression levels with NSCLC prognosis. Subgroup analysis of studies with sample sizes < 100 revealed a significant relation of high expression to poorer OS (HR: 1.51, 95% CI: 1.22–1.87). Conversely, when expression level was detected before chemotherapy, high expression was linked to improved OS (HR: 0.96, 95% CI: 0.93–0.99).
[CONCLUSION] This meta-analysis demonstrated that expression was not significantly associated with OS in the overall NSCLC population, but may have context-dependent prognostic value warranting further investigation.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15508-8.
[METHODS] Embase, the Cochrane Library, Web of Science, as well as PubMed were retrieved for eligible studies until September 18, 2025. Two reviewers independently extracted relevant data and appraised the study quality. The study quality was examined via the Newcastle-Ottawa Scale (NOS). Hazard Ratio (HR) with corresponding confidence intervals (CIs) for survival outcomes were calculated and summarized respectively. Subgroup analysis, regression analysis, sensitivity analysis and publication bias were conducted to investigate the findings further.
[RESULTS] 11 studies on 4,527 NSCLC patients were encompassed. All eligible studies had high methodological quality. The pooled HR of OS was 1.08 (95% CI: 0.91–1.29, = 0.356), suggesting no significant association of expression levels with NSCLC prognosis. Subgroup analysis of studies with sample sizes < 100 revealed a significant relation of high expression to poorer OS (HR: 1.51, 95% CI: 1.22–1.87). Conversely, when expression level was detected before chemotherapy, high expression was linked to improved OS (HR: 0.96, 95% CI: 0.93–0.99).
[CONCLUSION] This meta-analysis demonstrated that expression was not significantly associated with OS in the overall NSCLC population, but may have context-dependent prognostic value warranting further investigation.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15508-8.
같은 제1저자의 인용 많은 논문 (5)
- Diagnostic performance and generalizability of a clinical-ultrasound radiomics model for predicting extrathyroidal extension in thyroid carcinoma: a retrospective study.
- State-of-the-art review:Cardiac magnetic resonance imaging in primary cardiac tumors.
- Synergistic inhibitory effects of enzalutamide and its phase I metabolite on UDP-glucuronosyltransferase 1A1 (UGT1A1) and risk prediction of drug-drug interactions.
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.
- Clock genes in pancreatic disease progression: from circadian regulation to dysfunction.